| Symbol | AVXL |
|---|---|
| Name | ANAVEX LIFE SCIENCES CORP. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 51 WEST 52ND STREET,7TH FLOOR, NEW YORK, New York, 10019, United States |
| Telephone | +1 844 689-3939 |
| Fax | — |
| — | |
| Website | https://www.anavex.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001314052 |
| Description | Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimers disease, Parkinsons disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. Additional info from NASDAQ: |
New Form PREC14A - ANAVEX LIFE SCIENCES CORP. <b>Filed:</b> 2026-07-24 <b>AccNo:</b> 0000820434-26-000007 <b>Size:</b> 51 KB
Read more(99% Neutral) ANAVEX LIFE SCIENCES CORP. (AVXL) Announces Update on Collaboration with Floor New York
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Delinquent.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Delinquent.
Read more(99% Neutral) ANAVEX LIFE SCIENCES CORP. (AVXL) Announces New Board Appointment
Read moreNew Form NT 10-Q - ANAVEX LIFE SCIENCES CORP. <b>Filed:</b> 2026-05-11 <b>AccNo:</b> 0001731122-26-000702 <b>Size:</b> 28 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06245213 | A Study of ANAVEX3-71 in Adults With Schizophrenia | Phase2 | Schizophrenia | Active_Not_Recruiting | 2024-03-15 | 2025-06-30 | ClinicalTrials.gov |
| NCT04442945 | Phase 1 Study of ANAVEX3-71 | Phase1 | Healthy | Completed | 2020-07-03 | 2021-10-30 | ClinicalTrials.gov |
| NCT04304482 | ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome | Phase2 | Rett Syndrome | Completed | 2020-07-01 | 2023-06-30 | ClinicalTrials.gov |
| NCT04314934 | OLE of Phase 2b/3 Study ANAVEX2-73-AD-004 | Phase2 | Alzheimer Disease | Completed | 2019-10-10 | 2024-06-14 | ClinicalTrials.gov |
| NCT04575259 | OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study… | Phase2 | Parkinson Disease Dementia | Completed | 2019-10-10 | 2022-06-30 | ClinicalTrials.gov |
| NCT03941444 | ANAVEX2-73 Study in Patients With Rett Syndrome | Phase3 | Rett Syndrome | Completed | 2019-05-06 | 2021-09-30 | ClinicalTrials.gov |
| NCT03758924 | Study of ANAVEX2-73 in Patients With Rett Syndrome | Phase2 | Rett Syndrome | Completed | 2019-02-28 | 2020-10-30 | ClinicalTrials.gov |
| NCT03774459 | ANAVEX2-73 Study in Parkinson's Disease Dementia | Phase2 | Parkinsons Disease With Dementia | Completed | 2018-07-09 | 2020-09-30 | ClinicalTrials.gov |
| NCT03790709 | ANAVEX2-73 for Treatment of Early Alzheimer's Disease | Phase2 | Alzheimer Disease | Completed | 2018-07-03 | 2022-06-30 | ClinicalTrials.gov |
| NCT02756858 | An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's … | Phase2 | Alzheimer's Disease | Completed | 2016-03-01 | 2020-11-01 | ClinicalTrials.gov |
| NCT02244541 | Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2… | Phase2 | Alzheimer's Disease | Completed | 2014-12-01 | 2016-11-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ANAVEX2-73 Intravenous | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT02244541 |
| ANAVEX2-73 Oral | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT02244541 |
| Placebo | Other | Phase PHASE2 | Rett Syndrome | COMPLETED | NCT03758924 |
| ANAVEX2-73 | Other | Phase PHASE2 | Rett Syndrome | COMPLETED | NCT03758924 |
| Placebo oral capsules | Other | Phase PHASE2 | Schizophrenia | ACTIVE_NOT_RECRUITING | NCT06245213 |
| ANAVEX3-71 oral capsules | Other | Phase PHASE2 | Schizophrenia | ACTIVE_NOT_RECRUITING | NCT06245213 |
| Placebo oral capsule | Other | Phase PHASE2 | Parkinsons Disease With Dementia | COMPLETED | NCT03774459 |
| Mid dose ANAVEX2-73 | Other | Phase PHASE2 | Parkinsons Disease With Dementia | COMPLETED | NCT03774459 |
| High dose ANAVEX2-73 | Other | Phase PHASE2 | Parkinsons Disease With Dementia | COMPLETED | NCT03774459 |
| ANAVEX2-73 | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT02756858 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04442945 |
| ANAVEX3-71 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04442945 |
| Placebo | Other | Phase PHASE3 | Rett Syndrome | COMPLETED | NCT03941444 |
| ANAVEX2-73 | Other | Phase PHASE3 | Rett Syndrome | COMPLETED | NCT03941444 |
| Placebo oral capsule | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT03790709 |
| Mid dose ANAVEX2-73 | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT03790709 |
| High dose ANAVEX2-73 | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT03790709 |
| ANAVEX2-73 | Other | Phase PHASE2 | Parkinson Disease Dementia | COMPLETED | NCT04575259 |
| Placebo oral liquid | Other | Phase PHASE2 | Rett Syndrome | COMPLETED | NCT04304482 |
| ANAVEX2-73 oral liquid | Other | Phase PHASE2 | Rett Syndrome | COMPLETED | NCT04304482 |
| ANAVEX2-73 | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT04314934 |
| Placebo oral capsules | DRUG | Phase PHASE2 | Schizophrenia | ACTIVE_NOT_RECRUITING | NCT06245213 |
| ANAVEX3-71 oral capsules | DRUG | Phase PHASE2 | Schizophrenia | ACTIVE_NOT_RECRUITING | NCT06245213 |
| ANAVEX3-71 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04442945 |
| Placebo oral liquid | DRUG | Phase PHASE2 | Rett Syndrome | COMPLETED | NCT04304482 |
| ANAVEX2-73 oral liquid | DRUG | Phase PHASE2 | Rett Syndrome | COMPLETED | NCT04304482 |
| Placebo oral capsule | DRUG | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT03790709 |
| Mid dose ANAVEX2-73 | DRUG | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT03790709 |
| High dose ANAVEX2-73 | DRUG | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT03790709 |
| Placebo | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04442945 |
| ANAVEX2-73 | DRUG | Phase PHASE2 | Parkinson Disease Dementia | COMPLETED | NCT04575259 |
| ANAVEX2-73 Intravenous | DRUG | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT02244541 |
| ANAVEX2-73 Oral | DRUG | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT02244541 |